Introduction: Nonvalvular atrial fibrillation (NVAF) is associated with a fivefold excess risk of
stroke. Antithrombotic therapy is crucial to reduce the risk of stroke. During past decades …

Background Direct oral anticoagulants (DOAC) have been shown to be non-inferior to
traditional vitamin K antagonists in preventing stroke and arterial thromboembolism in …

Dabigatran is an oral direct thrombin inhibitor (DTI), which has a rapid onset of action and
can be given twice daily (bid) without anticoagulation monitoring. To determine the long term …

BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …

Atrial fibrillation (AF) is a cardiac arrhythmia associated to aging, arterial hypertension, valve
disease and other heart disorders. 1 Atrial fibrillation is associated to an increased mortality …

Importance of the field: Warfarin is the only oral anticoagulant recommended for the
prevention of ischemic stroke in atrial fibrillation. A newer and safer anticoagulant is needed …

Dabigatran is a direct inhibitor of thrombin that has recently been approved for primary and
secondary stroke prevention and prevention of systemic embolism in patients with atrial …

Background The newer oral anticoagulant dabigatran is considered to be more beneficial in
patients with non-valvular Atrial Fibrillation (AF) when compared to warfarin. However …

Stroke is a major health problem worldwide, and is often fatal or associated with poor long-
term outcomes. Atrial fibrillation (AF) is responsible for up to 20% of all strokes; and the risk …

Randomised clinical trials are presently the most objective tool for assessment of an
intervention, such as drug treatment or prevention effects, but the results may not necessarily …